Received Oct 24, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTAP | DTAP (INFANRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
| DTAPHEPBIP | DTAP + HEPB + IPV (PEDIARIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
| DTAPIPV | DTAP + IPV (KINRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
| FLU4 | INFLUENZA (SEASONAL) (FLULAVAL QUADRIVALENT) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
| HIBV | HIB (HIBERIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
| MENB | MENINGOCOCCAL B (BEXSERO) | NOVARTIS VACCINES AND DIAGNOSTICS | UNK | — | — |
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | UNK | — | — |
| RV1 | ROTAVIRUS (ROTARIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
After the monthly excursion, the products were use and they bring again the same vaccines; This non-serious case was reported by a nurse via call center representative and described the occurrence of incorrect storage of drug in an unspecified number of patients who received DTPa (Infanrix) for prophylaxis. Co-suspect products included DTPa-HBV-IPV (Pediarix) for prophylaxis, Rota (Rotarix liquid formulation) for prophylaxis, Hib (Hiberix) for prophylaxis, DTPa-IPV (Kinrix) for prophylaxis, Flu Seasonal QIV Quebec (FluLaval Quadrivalent) for prophylaxis, Men B NVS (Bexsero) for prophylaxis, Men ACWY-CRM NVS (Menveo) for prophylaxis, HAV (Havrix) for prophylaxis, HBV (Engerix B) for prophylaxis and DTPa (Reduced antigen) (Boostrix) for prophylaxis. On an unknown date, the patient received Infanrix, Pediarix, Rotarix liquid formulation, Hiberix, Kinrix, FluLaval Quadrivalent, Bexsero, Menveo, Havrix, Engerix B and Boostrix. On an unknown date, an unknown time after receiving Infanrix, Pediarix, Rotarix liquid formulation, Hiberix, Kinrix, FluLaval Quadrivalent, Bexsero, Menveo, Havrix, Engerix B and Boostrix, the patient experienced incorrect storage of drug (Verbatim: After the monthly excursion, the products were use and they bring again the same vaccines). The outcome of the incorrect storage of drug was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 25-SEP-2025 The healthcare professional mentioned that each excursion happened for the same products, but with different lot number. After the monthly excursion, the products were use and they bring again the same vaccines, but with different lot number. The vaccine administration facility was the same as primary reporter. During the call healthcare professional informed that after the monthly excursion, the products were use. The healthcare professional mentioned that they have no idea how many patients received the vaccines. In the adverse event report, they set all the vaccines, but it means that the patients received all of the vaccines. The batch number was not provided upon follow up with the reporter.